Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2022

Conditions
Kawasaki Disease
Interventions
DRUG

Anakinra

First two doses IV followed by SQ dosing

Trial Locations (1)

92191

Rady Children's Hospital San Diego, San Diego

All Listed Sponsors
collaborator

Boston Children's Hospital

OTHER

collaborator

Cedars-Sinai Medical Center

OTHER

lead

University of California, San Diego

OTHER

NCT02179853 - Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease | Biotech Hunter | Biotech Hunter